Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor—Acute Myeloid Leukemia: Systematic Review and Meta-Analysis
- 2 October 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (4), e221-e232
- https://doi.org/10.1016/j.clml.2021.09.020
Abstract
No abstract availableThis publication has 50 references indexed in Scilit:
- The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemiaLeukemia, 2013
- Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaHaematologica, 2011
- C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in miceProceedings of the National Academy of Sciences of the United States of America, 2011
- Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact ofC-KIT,FLT3, andJAK2mutations on clinical outcomeLeukemia & Lymphoma, 2009
- FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemiaBlood, 2008
- Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemiaBlood, 2007
- Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcriptsBlood, 2007
- Clinical implications of FLT3 mutations in pediatric AMLBlood, 2006
- FLT3: ITDoes matter in leukemiaLeukemia, 2003
- Molecular genetics of human leukemias: New insights into therapySeminars in Hematology, 2002